Research progress of rivaroxaban drug metabolism and gene polymorphism

VernacularTitle:利伐沙班药物代谢及基因多态性研究现状
Author: Xuyang MENG ; Yan WANG ; Huolan ZHU ; Zuowei PEI ; Chenguang YANG ; Fang WANG
From: Chinese Journal of General Practitioners 2021;20(6):705-709
CountryChina
Language:Chinese
Abstract: Rivaroxaban is one of the new oral anticoagulants (NOAC) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. It has clear pharmacokinetic parameters, stable plasma concentration, less drug-drug interaction and higher compliance of patients. However, the discrepancy of pharmacokinetics between individuals and drug-induced hemorrhage events frequently occur clinically, therefore the association of gene polymorphism with drug metabolism has become a research hotspot. This article reviews the research progress on pharmacokinetic characteristics of rivaroxaban and its relationship with gene polymorphism, to provide a reference for the individualized rational use of rivaroxaban.